Last reviewed · How we verify

EP2006 — Competitive Intelligence Brief

EP2006 (EP2006) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Erythropoietin receptor agonist (biosimilar). Area: Hematology/Oncology.

phase 3 Erythropoietin receptor agonist (biosimilar) Erythropoietin receptor (EPOR) Hematology/Oncology Small molecule Live · refreshed every 30 min

Target snapshot

EP2006 (EP2006) — Sandoz. EP2006 is a biosimilar of epoetin alfa that stimulates erythropoiesis by binding to and activating the erythropoietin receptor on bone marrow progenitor cells.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
EP2006 TARGET EP2006 Sandoz phase 3 Erythropoietin receptor agonist (biosimilar) Erythropoietin receptor (EPOR)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Erythropoietin receptor agonist (biosimilar) class)

  1. Sandoz · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). EP2006 — Competitive Intelligence Brief. https://druglandscape.com/ci/ep2006. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: